H. Lundbeck A/S (HLUYY) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
H. Lundbeck A/S (HLUYY) trades at $22.00. H. Lundbeck A/S is a biopharmaceutical company focused on researching, developing, and marketing pharmaceuticals for psychiatric and neurological disorders. Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Mar 18, 2026Analyst Coverage for HLUYY: HLUYY does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates HLUYY against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
HLUYY: 2/3 scored disciplines lean bullish. Dominant signal: Ken Griffin bearish.
How is this calculated? →H. Lundbeck A/S (HLUYY) Healthcare & Pipeline Overview
H. Lundbeck A/S is a global biopharmaceutical company specializing in treatments for psychiatric and neurological disorders, offering key products like Abilify Maintena and Brintellix/Trintellix. With a focus on addressing unmet needs in mental health, Lundbeck operates in a competitive market landscape, marked by innovation and regulatory complexities.
What Is the Investment Thesis for HLUYY?
H. Lundbeck A/S presents a focused investment opportunity within the biopharmaceutical sector, driven by its specialization in psychiatric and neurological disorders. The company's established product portfolio, including key drugs like Abilify Maintena and Brintellix/Trintellix, generates consistent revenue streams. A gross margin of 79.6% highlights efficient operations. Upcoming data from the Verantos partnership could provide real-world evidence supporting migraine therapy, potentially boosting Vyepti sales. The company's dividend yield of 2.53% offers income potential. Potential risks include patent expirations and competition from generic drugs, which could impact future revenue. The P/E ratio of 11.3 suggests a reasonable valuation relative to earnings.
Based on FMP financials and quantitative analysis
HLUYY Key Highlights
H. Lundbeck A/S specializes in pharmaceuticals for psychiatric and neurological disorders, a growing area of unmet medical need.
- The company maintains a strong gross margin of 79.6%, indicating efficient cost management in its operations.
- Key products include Abilify Maintena for schizophrenia and Brintellix/Trintellix for depression, contributing significantly to revenue.
- H. Lundbeck has a dividend yield of 2.53%, offering income to investors.
- The company's P/E ratio stands at 11.3, suggesting a potentially undervalued stock compared to its earnings.
Who Are HLUYY's Competitors?
HLUYY is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ABCZF Abcam plc | $22.25 | +0.68% | $5.12B | 46 |
| ANHGY Mediclinic International plc | $5.49 | +0.00% | $4.05B | 44 |
| ASPHF Ascentage Pharma Group International | $4.53 | +0.00% | $1.69B | 51 |
| DPHAY Dechra Pharmaceuticals PLC | $98.00 | +1.98% | $6.00B | 48 |
| DUTV Digital Utilities Ventures, Inc. | $0.55 | +3.46% | $1.91B | — |
| ZTS Zoetis Inc. | $75.44 | -1.62% | $31.6B | 85 |
| ITCI ITCI | $131.87 | +0.00% | $14.1B | 63 |
| ESALF Eisai Co., Ltd. | $29.90 | +0.00% | $8.44B | 61 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are HLUYY's Key Strengths?
Specialized expertise in psychiatric and neurological disorders.
- Established product portfolio with key drugs like Abilify Maintena and Brintellix/Trintellix.
- Strong gross margin of 79.6%.
- Global presence with sales in Europe, North America, and other international markets.
What Are HLUYY's Weaknesses?
Reliance on a limited number of key products.
- Exposure to patent expirations and generic competition.
- High research and development costs.
- Dependence on regulatory approvals for new products.
What Could Drive HLUYY Stock Higher?
Potential positive clinical trial results for new drug candidates in the pipeline.
- Expansion of existing product sales in emerging markets.
- Data release from the Verantos partnership study on Vyepti for migraine therapy.
- Strategic collaborations to develop new therapies for psychiatric and neurological disorders.
- Lifecycle management initiatives to extend the revenue streams of existing products.
What Are the Key Risks for HLUYY?
Patent expirations on key drugs leading to generic competition.
- Pricing pressures from healthcare providers and payers.
- Unfavorable regulatory changes impacting drug approvals and market access.
- Clinical trial failures and delays in product approvals.
- Competition from other pharmaceutical companies in the psychiatric and neurological disorder market.
What Are the Growth Opportunities for HLUYY?
- Growth opportunity 1: Expansion of Vyepti for Migraine Prevention: Vyepti, H. Lundbeck's migraine prevention drug, represents a significant growth opportunity. The global migraine market is projected to reach $3.5 billion by 2027, driven by increasing prevalence and demand for effective treatments. H. Lundbeck's partnership with Verantos to generate real-world evidence could strengthen Vyepti's market position and drive adoption among healthcare providers. Successful clinical trials and positive patient outcomes could further accelerate growth in this segment.
- Growth opportunity 2: Strategic Partnerships and Collaborations: H. Lundbeck's collaboration with Rgenta Therapeutics, Inc. to develop new therapeutic approaches represents a key growth driver. By partnering with innovative biotech companies, H. Lundbeck can access novel technologies and expand its pipeline of potential drug candidates. These collaborations can lead to the development of breakthrough treatments for psychiatric and neurological disorders, creating new revenue streams and enhancing the company's competitive advantage. The success of these partnerships will depend on effective collaboration and successful clinical trial outcomes.
- Growth opportunity 3: Geographic Expansion into Emerging Markets: Expanding into emerging markets represents a significant growth opportunity for H. Lundbeck. Countries in Asia, Latin America, and Eastern Europe are experiencing increasing demand for mental health treatments due to rising awareness and improved access to healthcare. By establishing a presence in these markets, H. Lundbeck can tap into new customer segments and diversify its revenue base. This expansion will require strategic investments in infrastructure, regulatory compliance, and local partnerships.
- Growth opportunity 4: Lifecycle Management of Existing Products: H. Lundbeck can extend the revenue streams of its existing products through lifecycle management strategies. This includes developing new formulations, indications, and delivery methods for drugs like Abilify Maintena and Brintellix/Trintellix. By continuously innovating and improving its existing product portfolio, H. Lundbeck can maintain its competitive edge and capture additional market share. Successful lifecycle management requires ongoing investment in research and development and effective marketing strategies.
- Growth opportunity 5: Focus on Personalized Medicine: The growing trend towards personalized medicine offers a significant growth opportunity for H. Lundbeck. By leveraging genetic and biomarker data, the company can develop targeted therapies that are tailored to individual patient needs. This approach can improve treatment outcomes and reduce side effects, leading to increased patient satisfaction and market adoption. H. Lundbeck's investment in research and development capabilities and its partnerships with diagnostic companies will be crucial for capitalizing on this opportunity.
What Are HLUYY's Competitive Advantages?
- Patent protection on key drugs provides a period of market exclusivity.
- Strong brand reputation in the field of psychiatric and neurological disorders.
- Specialized expertise in developing and marketing treatments for mental health conditions.
- Established relationships with healthcare providers and distributors.
- High barriers to entry due to the complex regulatory environment and high cost of drug development.
What Does HLUYY Do?
Founded in 1915 and headquartered in Valby, Denmark, H. Lundbeck A/S has evolved into a global biopharmaceutical company dedicated to developing and marketing pharmaceuticals for the treatment of psychiatric and neurological disorders. The company's portfolio includes products addressing a range of conditions, including schizophrenia (Abilify Maintena), depression (Brintellix/Trintellix, Cipralex/Lexapro, Rexulti/Rxulti), migraine (Vyepti), Alzheimer's disease (Ebixa), Parkinson's disease (Azilect), epilepsy (Sabril), and Huntington's disease (Xenazine), among others. H. Lundbeck sells its products primarily to distributors of pharmaceuticals, pharmacies, and hospitals across Europe, North America, and other international markets. The company emphasizes research and development to expand its product offerings and address unmet needs in mental health. Its partnership with Verantos focuses on leveraging real-world evidence to support migraine therapy, while its collaboration with Rgenta Therapeutics, Inc. aims to advance new therapeutic approaches. With a workforce of 5353 employees, H. Lundbeck continues to innovate and expand its reach in the global pharmaceutical market.
What Products and Services Does HLUYY Offer?
- Researches and develops pharmaceutical products for psychiatric and neurological disorders.
- Manufactures and markets a range of drugs for conditions like schizophrenia, depression, and Alzheimer's disease.
- Sells its products to distributors, pharmacies, and hospitals worldwide.
- Partners with other companies to develop new therapies and expand its product pipeline.
- Focuses on addressing unmet needs in mental health and neurological disorders.
- Conducts clinical trials to evaluate the safety and efficacy of its drugs.
- Seeks regulatory approvals from agencies like the FDA and EMA to market its products.
How Does HLUYY Make Money?
- Develops and patents pharmaceutical products for psychiatric and neurological disorders.
- Generates revenue through the sale of branded drugs to distributors, pharmacies, and hospitals.
- Reinvests a portion of its revenue into research and development to discover new drugs and improve existing ones.
- Forms partnerships and collaborations to expand its product pipeline and market reach.
What Industry Does HLUYY Operate In?
H. Lundbeck A/S operates within the specialty and generic drug manufacturing industry, a segment of the healthcare sector characterized by intense competition and regulatory scrutiny. The market for psychiatric and neurological disorder treatments is expanding due to increased awareness, aging populations, and advancements in diagnostic capabilities. Companies like H. Lundbeck face competition from both established pharmaceutical giants and smaller, innovative biotech firms. The industry is also influenced by factors such as patent expirations, pricing pressures, and the rising cost of research and development. H. Lundbeck's focus on specific therapeutic areas allows it to compete effectively by developing specialized treatments and building strong relationships with healthcare providers.
Who Are HLUYY's Key Customers?
- Distributors of pharmaceuticals
- Pharmacies
- Hospitals
- Patients with psychiatric and neurological disorders
- Healthcare providers (doctors, psychiatrists, neurologists)
Key Financial Metrics
Return on equity for H. Lundbeck A/S stands at 14.8%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 7.1%, showing how much profit it generates from its asset base. HLUYY trades at a trailing price-to-earnings ratio of 11.33, below the Healthcare sector average of ~23x. Its free cash flow yield is 12.7%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.41 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 8.7%, the inverse of the P/E and a quick read on earnings relative to price.
Company Profile
H. Lundbeck A/S operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Valby, DK. The company is led by CEO Deborah Dunsire. HLUYY has traded publicly since 2012.
HLUYY Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Specialized expertise in psychiatric and neurological disorders.
- Established product portfolio with key drugs like Abilify Maintena and Brintellix/Trintellix.
- Strong gross margin of 79.6%.
- Global presence with sales in Europe, North America, and other international markets.
Bear Case
- Reliance on a limited number of key products.
- Exposure to patent expirations and generic competition.
- High research and development costs.
- Dependence on regulatory approvals for new products.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · August 2026
HLUYY Latest News
No recent news available for HLUYY.
HLUYY Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for HLUYY.
Price Targets
Wall Street price target analysis for HLUYY.
HLUYY MoonshotScore
What does this score mean?
The MoonshotScore rates HLUYY 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Deborah Dunsire
CEO
Deborah Dunsire is the CEO of H. Lundbeck A/S, bringing extensive experience in the pharmaceutical industry. Prior to joining Lundbeck, she served as President and CEO of XTuit Pharmaceuticals and previously held leadership roles at Millennium Pharmaceuticals and Novartis. She has a proven track record in drug development, commercialization, and strategic management. Her experience spans various therapeutic areas, including oncology and neuroscience, making her well-suited to lead H. Lundbeck's focus on psychiatric and neurological disorders.
Track Record: Under Deborah Dunsire's leadership, H. Lundbeck A/S has focused on strengthening its pipeline and expanding its global reach. Key milestones include strategic partnerships to develop new therapies and efforts to enhance the commercial performance of existing products. Her focus on innovation and patient-centric solutions has helped to position H. Lundbeck as a leader in the treatment of psychiatric and neurological disorders.
H. Lundbeck A/S ADR Information Unsponsored
An American Depositary Receipt (ADR) is a certificate representing shares of a foreign company trading on U.S. stock exchanges. HLUYY is a Level 1 ADR, meaning it trades over-the-counter (OTC) without requiring the same level of regulatory compliance as listed stocks. This allows U.S. investors to invest in H. Lundbeck A/S more easily, though it comes with certain risks associated with OTC trading.
- Home Market Ticker: Nasdaq Copenhagen, Denmark
- ADR Level: 1
- ADR Ratio: 1:1
- Home Market Ticker: HLUY
HLUYY OTC Market Information
The OTC Other tier represents the lowest tier of the over-the-counter (OTC) market. Companies in this tier often have limited financial disclosure and may not meet minimum listing requirements of major exchanges like the NYSE or NASDAQ. Investing in OTC Other stocks carries higher risks due to the potential for less transparency and greater price volatility compared to stocks listed on regulated exchanges. Investors should exercise caution and conduct thorough due diligence before investing in HLUYY.
- OTC Tier: OTC Other
- Limited financial disclosure and transparency.
- Potential for price manipulation and fraud.
- Higher price volatility due to lower trading volume.
- Greater difficulty in finding reliable information about the company.
- Risk of delisting or suspension of trading.
- Verify the company's registration and regulatory filings.
- Review the company's financial statements, if available.
- Assess the company's business model and competitive landscape.
- Evaluate the company's management team and track record.
- Check for any legal or regulatory issues.
- Monitor trading volume and price volatility.
- Consult with a financial advisor before investing.
- Established history as a biopharmaceutical company.
- Presence in the psychiatric and neurological disorder treatment market.
- Partnerships with reputable organizations.
- Patent protection on key drugs.
- Experienced management team.
What Investors Ask About H. Lundbeck A/S (HLUYY) — Healthcare
What does H. Lundbeck A/S do?
H. Lundbeck A/S is a global biopharmaceutical company specializing in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders. Its key products target conditions like schizophrenia, depression, migraine, Alzheimer's disease, and Parkinson's disease. The company operates across Europe, North America, and internationally, selling its products to distributors, pharmacies, and hospitals. H.
What do analysts say about HLUYY stock?
Analyst coverage of HLUYY is limited due to its OTC listing and ADR Level 1 status. Available reports suggest a focus on H. Lundbeck's pipeline development and the performance of key drugs like Abilify Maintena and Brintellix/Trintellix.
What are the main risks for HLUYY?
The main risks for HLUYY include patent expirations on key drugs, which could lead to generic competition and reduced revenue. Pricing pressures from healthcare providers and payers also pose a threat to profitability. Unfavorable regulatory changes, such as stricter approval requirements or pricing controls, could impact the company's ability to market its products.
What are the key factors to evaluate for HLUYY?
Evaluate HLUYY on fundamentals, analyst consensus, and risk factors. P/E: 11.3x vs the S&P 500's ~20-25x. H. Not financial advice.
How frequently does HLUYY data refresh on this page?
HLUYY's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven HLUYY's recent stock price performance?
H. Lundbeck A/S (HLUYY) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Specialized expertise in psychiatric and neurological disorders. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider HLUYY overvalued or undervalued right now?
H. Lundbeck A/S (HLUYY) trades at 11.3x earnings. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research HLUYY before investing?
Before investing in H. Lundbeck A/S (HLUYY), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- OTC stocks carry higher risks than exchange-listed stocks.
- Investment decisions should be made after consulting with a financial advisor.